SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized. Xeris Biopharma Holdings, Inc. By /s/ Paul R. Edick Paul R. Edick Chief Executive Officer and Chairman Date March 11, 2022 Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below as of March 11, 2022, by the following persons on behalf of the registrant and in the capacities indicated. SIGNATURE TITLE /s/ Paul R. Edick Chief Executive Officer and Chairman (Principal Executive Officer) Paul R. Edick /s/ Steven M. Pieper Chief Financial Officer (Principal Financial Officer and Principal Accounting officer) Steven M. Pieper /s/ B.J. Bormann Director B.J. Bormann /s/ Dawn Halkuff Director Dawn Halkuff /s/ Garheng Kong Director Garheng Kong /s/ Jeffrey Sherman Director Jeffrey Sherman /s/ John H. Johnson Director John H. Johnson /s/ John Schmid Director John Schmid /s/ Marla Persky Director Marla Persky 132
RkJQdWJsaXNoZXIy NTIzOTM0